

# Paul Gregorevic

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5945789/paul-gregorevic-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124  
papers

6,777  
citations

45  
h-index

81  
g-index

132  
ext. papers

7,836  
ext. citations

8.2  
avg, IF

5.43  
L-index

#	Paper	IF	Citations
124	Expanding the MuRF1 Universe with Quantitative Ubiquitylomics.. <i>Function</i> , <b>2021</b> , 2, zqab058	6.1	
123	Bone Morphogenetic Protein 7 Gene Delivery Improves Cardiac Structure and Function in a Murine Model of Diabetic Cardiomyopathy. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 719290	5.6	3
122	Phosphorylation of ERK and dystrophin S3059 protects against inflammation-associated C2C12 myotube atrophy. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C956-C965	5.4	3
121	Sex-Specific Control of Human Heart Maturation by the Progesterone Receptor. <i>Circulation</i> , <b>2021</b> , 143, 1614-1628	16.7	6
120	Yap regulates skeletal muscle fatty acid oxidation and adiposity in metabolic disease. <i>Nature Communications</i> , <b>2021</b> , 12, 2887	17.4	3
119	Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner. <i>iScience</i> , <b>2021</b> , 24, 102537	6.1	3
118	The regulation of polyamine pathway proteins in models of skeletal muscle hypertrophy and atrophy: a potential role for mTORC1. <i>American Journal of Physiology - Cell Physiology</i> , <b>2021</b> , 320, C987-C999	5.4	3
117	genotype influences skeletal muscle mass regulation and response to dexamethasone. <i>Science Advances</i> , <b>2021</b> , 7,	14.3	2
116	Dynamic Changes to the Skeletal Muscle Proteome and Ubiquitinome Induced by the E3 Ligase, ASB2. <i>Molecular and Cellular Proteomics</i> , <b>2021</b> , 20, 100050	7.6	4
115	Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	11
114	Bone Geometry Is Altered by Follistatin-Induced Muscle Growth in Young Adult Male Mice. <i>JBMR Plus</i> , <b>2021</b> , 5, e10477	3.9	1
113	Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	11
112	Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic mouse lines. <i>Molecular Metabolism</i> , <b>2021</b> , 53, 101292	8.8	1
111	Gene therapy targeting cardiac phosphoinositide 3-kinase (p110) attenuates cardiac remodeling in type 2 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2020</b> , 318, H840-H852	5.2	13
110	Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes. <i>FASEB Journal</i> , <b>2020</b> , 34, 5697-5714	0.9	3
109	TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass. <i>Frontiers in Physiology</i> , <b>2020</b> , 11, 560225	4.6	3
108	Integrated Glycoproteomics Identifies a Role of N-Glycosylation and Galectin-1 on Myogenesis and Muscle Development. <i>Molecular and Cellular Proteomics</i> , <b>2020</b> , 20, 100030	7.6	13

107	Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed Endothelium. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2019</b> , 14, 261-269	6.4	2
106	Activin A-Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. <i>Endocrinology</i> , <b>2019</b> , 160, 2417-2426	4.8	8
105	Treatment of type 2 diabetes with the designer cytokine IC7Fc. <i>Nature</i> , <b>2019</b> , 574, 63-68	50.4	30
104	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2019</b> , 10, 1241-1257	10.3	24
103	Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity. <i>Journal of Physiology</i> , <b>2019</b> , 597, 4831-4850	3.9	7
102	The E3 ligase MARCH5 is a PPAR $\alpha$ target gene that regulates mitochondria and metabolism in adipocytes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2019</b> , 316, E293-E304	6	5
101	Skeletal muscle-specific overexpression of heat shock protein 72 improves skeletal muscle insulin-stimulated glucose uptake but does not alter whole body metabolism. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1928-1936	6.7	13
100	Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling. <i>Clinical Science</i> , <b>2018</b> , 132, 381-397	6.5	10
99	Molecular characterization of latent GDF8 reveals mechanisms of activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E866-E875	11.5	23
98	The Hippo Signaling Pathway in the Regulation of Skeletal Muscle Mass and Function. <i>Exercise and Sport Sciences Reviews</i> , <b>2018</b> , 46, 92-96	6.7	23
97	Extracellular Vesicles Provide a Means for Tissue Crosstalk during Exercise. <i>Cell Metabolism</i> , <b>2018</b> , 27, 237-251.e4	24.6	257
96	The Effect of ACTN3 Gene Doping on Skeletal Muscle Performance. <i>American Journal of Human Genetics</i> , <b>2018</b> , 102, 845-857	11	9
95	Generation of MicroRNA-34 Sponges and Tough Decoys for the Heart: Developments and Challenges. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1090	5.6	13
94	Phosphoinositide 3-kinase (p110 $\alpha$ ) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. <i>Clinical Science</i> , <b>2017</b> , 131, 1345-1360	6.5	33
93	Specific targeting of TGF- $\beta$ family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E5266-E5275	11.5	54
92	Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E8372-E8381	11.5	239
91	Induction of experimental autoimmune orchitis in mice: responses to elevated circulating levels of the activin-binding protein, follistatin. <i>Reproduction</i> , <b>2017</b> , 154, 293-305	3.8	16
90	Regulation of Tissue Growth by the Mammalian Hippo Signaling Pathway. <i>Frontiers in Physiology</i> , <b>2017</b> , 8, 942	4.6	29

89	Disruption of the Class IIa HDAC Corepressor Complex Increases Energy Expenditure and Lipid Oxidation. <i>Cell Reports</i> , <b>2016</b> , 16, 2802-2810	10.6	48
88	Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 348ra98	17.5	45
87	Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia. <i>Cancer Research</i> , <b>2016</b> , 76, 5372-82	10.1	43
86	The TGF- $\beta$ Signalling Network in Muscle Development, Adaptation and Disease. <i>Advances in Experimental Medicine and Biology</i> , <b>2016</b> , 900, 97-131	3.6	33
85	Modulating myosin restores muscle function in a mouse model of nemaline myopathy. <i>Annals of Neurology</i> , <b>2016</b> , 79, 717-725	9.4	13
84	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. <i>Diabetes</i> , <b>2016</b> , 65, 1085-98	0.9	34
83	Integrated expression analysis of muscle hypertrophy identifies as a negative regulator of muscle mass. <i>JCI Insight</i> , <b>2016</b> , 1,	9.9	29
82	Using AAV vectors expressing the $\alpha$ -adrenoceptor or associated G $\beta$ proteins to modulate skeletal muscle mass and muscle fibre size. <i>Scientific Reports</i> , <b>2016</b> , 6, 23042	4.9	16
81	Glucose-6-phosphate dehydrogenase contributes to the regulation of glucose uptake in skeletal muscle. <i>Molecular Metabolism</i> , <b>2016</b> , 5, 1083-1091	8.8	15
80	Skeletal muscle-specific overexpression of IGFBP-2 promotes a slower muscle phenotype in healthy but not dystrophic mdx mice and does not affect the dystrophic pathology. <i>Growth Hormone and IGF Research</i> , <b>2016</b> , 30-31, 1-10	2	10
79	The atypical 'b' splice variant of phospholipase C $\beta$ promotes cardiac contractile dysfunction. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2015</b> , 84, 95-103	5.8	7
78	Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival. <i>Cell</i> , <b>2015</b> , 162, 1365-78	56.2	82
77	Development of novel activin-targeted therapeutics. <i>Molecular Therapy</i> , <b>2015</b> , 23, 434-44	11.7	40
76	Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravis. <i>Physiological Reports</i> , <b>2015</b> , 3, e12658	2.6	12
75	miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. <i>Clinical Science</i> , <b>2015</b> , 129, 1237-49	6.5	161
74	Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. <i>Scientific Reports</i> , <b>2015</b> , 5, 17535	4.9	23
73	The Hippo pathway effector YAP is a critical regulator of skeletal muscle fibre size. <i>Nature Communications</i> , <b>2015</b> , 6, 6048	17.4	81
72	Elevated expression of activins promotes muscle wasting and cachexia. <i>FASEB Journal</i> , <b>2014</b> , 28, 1711-23	3.9	130

71	TGF $\beta$ and BMP signaling in skeletal muscle: potential significance for muscle-related disease. <i>Trends in Endocrinology and Metabolism</i> , <b>2014</b> , 25, 464-71	8.8	111
70	Functional $\beta$ -adrenoceptors are important for early muscle regeneration in mice through effects on myoblast proliferation and differentiation. <i>PLoS ONE</i> , <b>2014</b> , 9, e101379	3.7	8
69	Abnormal mitochondrial L-arginine transport contributes to the pathogenesis of heart failure and reoxygenation injury. <i>PLoS ONE</i> , <b>2014</b> , 9, e104643	3.7	14
68	Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. <i>FASEB Journal</i> , <b>2014</b> , 28, 5097-110	0.9	61
67	Phosphorylation within the cysteine-rich region of dystrophin enhances its association with $\beta$ -dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6697-711	5.6	10
66	Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy. <i>PLoS ONE</i> , <b>2014</b> , 9, e90337	3.7	58
65	ACTN3 genotype influences muscle performance through the regulation of calcineurin signaling. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 4255-63	15.9	84
64	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Cell Biology</i> , <b>2013</b> , 203, 345-57	7.3	128
63	miR-206 represses hypertrophy of myogenic cells but not muscle fibers via inhibition of HDAC4. <i>PLoS ONE</i> , <b>2013</b> , 8, e73589	3.7	63
62	The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass. <i>Journal of Experimental Medicine</i> , <b>2013</b> , 210, 210120IA54	16.6	1
61	Activin signaling regulates Sertoli cell differentiation and function. <i>Endocrinology</i> , <b>2012</b> , 153, 6065-77	4.8	48
60	Phosphoinositide 3-kinase p110 $\delta$ is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. <i>Circulation: Heart Failure</i> , <b>2012</b> , 5, 523-34	7.6	89
59	Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. <i>Journal of Cell Biology</i> , <b>2012</b> , 197, 997-1008	7.3	133
58	Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation. <i>PLoS ONE</i> , <b>2012</b> , 7, e51627	3.7	8
57	Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 17615-20	11.5	330
56	Suppression of microRNA-29 expression by TGF- $\beta$ 1 promotes collagen expression and renal fibrosis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 252-65	12.7	385
55	Lentiviral transduction of rat Sertoli cells as a means to modify gene expression. <i>Spermatogenesis</i> , <b>2012</b> , 2, 279-284		2
54	TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 13805-14	5.4	202

53	Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. <i>Molecular Therapy</i> , <b>2011</b> , 19, 36-45	11.7	74
52	Generation of a specific activin antagonist by modification of the activin A propeptide. <i>Endocrinology</i> , <b>2011</b> , 152, 3758-68	4.8	19
51	Preclinical studies for gene therapy of Duchenne muscular dystrophy. <i>Journal of Child Neurology</i> , <b>2010</b> , 25, 1149-57	2.5	8
50	Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. <i>Molecular Therapy</i> , <b>2010</b> , 18, 206-13	11.7	49
49	Combinatorial Gene Therapy Strategies for Treating Muscular Dystrophies <b>2010</b> , 117-139		
48	Erratum to Efficient Transduction of Skeletal Muscle Using Vectors Based on Adeno-associated Virus Serotype 6 <i>Molecular Therapy</i> , <b>2009</b> , 17, 1482	11.7	78
47	Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. <i>Molecular Therapy</i> , <b>2009</b> , 17, 1427-33	11.7	35
46	Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. <i>Hypertension</i> , <b>2009</b> , 53, 694-700	8.5	36
45	Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. <i>Molecular Therapy</i> , <b>2008</b> , 16, 657-64	11.7	96
44	Microtrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. <i>Molecular Therapy</i> , <b>2008</b> , 16, 1539-45	11.7	93
43	Functional deficits in nNOS $\mu$ -deficient skeletal muscle: myopathy in nNOS knockout mice. <i>PLoS ONE</i> , <b>2008</b> , 3, e3387	3.7	67
42	Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. <i>Muscle and Nerve</i> , <b>2008</b> , 37, 104-6	3.4	27
41	rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles. <i>Traffic</i> , <b>2007</b> , 8, 1424-39	5.7	43
40	Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. <i>Human Gene Therapy</i> , <b>2007</b> , 18, 18-26	4.8	119
39	Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. <i>Molecular Therapy</i> , <b>2007</b> , 15, 320-9	11.7	142
38	Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. <i>Molecular Therapy</i> , <b>2007</b> , 15, 1160-6	11.7	192
37	Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. <i>Molecular Therapy</i> , <b>2007</b> , 15, 1086-92	11.7	110
36	Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. <i>Human Molecular Genetics</i> , <b>2007</b> , 16, 2105-13	5.6	40

35	Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2007</b> , 1772, 243-62	6.9	79
34	Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. <i>Molecular Therapy</i> , <b>2006</b> , 13, 241-9	11.7	71
33	rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. <i>Nature Medicine</i> , <b>2006</b> , 12, 787-9	50.5	248
32	Immunity to Adeno-Associated Virus-Mediated Gene Transfer in a Random-Bred Canine Model of Duchenne Muscular Dystrophy. <i>Human Gene Therapy</i> , <b>2006</b> , 061218064941001	4.8	
31	Interleukin-15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. <i>American Journal of Pathology</i> , <b>2005</b> , 166, 1131-41	5.8	49
30	Functional enhancement of skeletal muscle by gene transfer. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , <b>2005</b> , 16, 875-87, vii-viii	2.3	2
29	Chronic beta-agonist administration affects cardiac function of adult but not old rats, independent of beta-adrenoceptor density. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2005</b> , 289, H344-9	5.2	24
28	Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. <i>Molecular Therapy</i> , <b>2005</b> , 12, 441-50	11.7	60
27	Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. <i>Molecular Therapy</i> , <b>2004</b> , 10, 671-8	11.7	195
26	Systemic delivery of genes to striated muscles using adeno-associated viral vectors. <i>Nature Medicine</i> , <b>2004</b> , 10, 828-34	50.5	519
25	Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. <i>Journal of Physiology</i> , <b>2004</b> , 555, 175-88	3.9	82
24	Changes in contractile activation characteristics of rat fast and slow skeletal muscle fibres during regeneration. <i>Journal of Physiology</i> , <b>2004</b> , 558, 549-60	3.9	21
23	The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 299-310	14.3	68
22	Administration of insulin-like growth factor-I improves fatigue resistance of skeletal muscles from dystrophic mdx mice. <i>Muscle and Nerve</i> , <b>2004</b> , 30, 295-304	3.4	44
21	Beta2-adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. <i>Journal of Applied Physiology</i> , <b>2004</b> , 96, 1385-92	3.7	74
20	Viral vectors for gene transfer to striated muscle. <i>Current Opinion in Molecular Therapeutics</i> , <b>2004</b> , 6, 491-8		15
19	Gene therapy for muscular dystrophy - a review of promising progress. <i>Expert Opinion on Biological Therapy</i> , <b>2003</b> , 3, 803-14	5.4	21
18	Endurance training adaptations modulate the redox-force relationship of rat isolated slow-twitch skeletal muscles. <i>Clinical and Experimental Pharmacology and Physiology</i> , <b>2003</b> , 30, 77-81	3	12

17	Gene therapy for muscular dystrophy ? a review of promising progress. <i>Expert Opinion on Biological Therapy</i> , <b>2003</b> , 3, 803-814	5.4	20
16	Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol. <i>Muscle and Nerve</i> , <b>2002</b> , 25, 194-201	3.4	20
15	Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2002</b> , 283, R1386-94	3.2	56
14	Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. <i>Medicine and Science in Sports and Exercise</i> , <b>2002</b> , 34, 630-6	1.2	11
13	Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 2263-72	5.8	97
12	Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles. <i>Medicine and Science in Sports and Exercise</i> , <b>2002</b> , 34, 630-636	1.2	10
11	Hyperbaric oxygen modulates antioxidant enzyme activity in rat skeletal muscles. <i>European Journal of Applied Physiology</i> , <b>2001</b> , 86, 24-7	3.4	52
10	In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. <i>Human Gene Therapy</i> , <b>2001</b> , 12, 629-42	4.8	79
9	IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. <i>Neuromuscular Disorders</i> , <b>2001</b> , 11, 260-8	2.9	73
8	Redox modulation of maximum force production of fast- and slow-twitch skeletal muscles of rats and mice. <i>Journal of Applied Physiology</i> , <b>2001</b> , 90, 832-8	3.7	26
7	Specific force of the rat extraocular muscles, levator and superior rectus, measured in situ. <i>Journal of Neurophysiology</i> , <b>2001</b> , 85, 1027-32	3.2	16
6	Functional properties of regenerating skeletal muscle following LIF administration. <i>Muscle and Nerve</i> , <b>2000</b> , 23, 1586-8	3.4	11
5	Leukemia inhibitory factor ameliorates muscle fiber degeneration in the mdx mouse. <i>Muscle and Nerve</i> , <b>2000</b> , 23, 1700-5	3.4	36
4	Hyperbaric oxygen improves contractile function of regenerating rat skeletal muscle after myotoxic injury. <i>Journal of Applied Physiology</i> , <b>2000</b> , 89, 1477-82	3.7	20
3	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle		1
2	Molecular characterization of latent GDF8 reveals mechanisms of activation		2
1	Therapeutic Gene Transfer to Skeletal Muscle123-128		